Whether and how disutilities of adverse events were used in the economic evaluation of drug therapy for cancer treatment
Y Lu, Z Dai, F Chang, L Wang, J He, P Shi, H Zhang… - …, 2023 - Springer
Background The disutilities of adverse events (AEs) are important inputs for cost-utility
analysis (CUA), reflecting the impacts of AEs on health outcomes. Health technology …
analysis (CUA), reflecting the impacts of AEs on health outcomes. Health technology …
[HTML][HTML] Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth …
L Zhu, M Wang, X Luo, H Li, H Shan… - Annals of Translational …, 2022 - ncbi.nlm.nih.gov
Background Hormone receptor-positive (HR+) and human epidermal growth factor receptor-
2 negative (HER2−) breast cancer is the most common molecular subtype of breast cancer …
2 negative (HER2−) breast cancer is the most common molecular subtype of breast cancer …
Cost effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2− Metastatic breast cancer in postmenopausal women in the USA
PP Masurkar, H Damgacioglu, AA Deshmukh… - …, 2023 - Springer
Abstract Background and Objective Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors
improve progression-free survival when combined with endocrine therapies in patients with …
improve progression-free survival when combined with endocrine therapies in patients with …
US payer budget impact of using an AI-augmented cancer risk discrimination digital histopathology platform to identify high-risk of recurrence in women with early …
SF Masud, N Mark, T Goss, D Malinowski… - Journal of Medical …, 2024 - Taylor & Francis
Aims Use of gene expression signatures to predict adjuvant chemotherapy benefit in women
with early-stage breast cancer is increasing. However, high cost, limited access, and …
with early-stage breast cancer is increasing. However, high cost, limited access, and …
Comparison of healthcare resource utilization and costs of patients with HR+/HER2-advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors
R Burne, S Balu, A Guérin, R Bungay… - Journal of medical …, 2021 - Taylor & Francis
Aims To assess healthcare resource utilization (HRU) and healthcare costs among women
with hormone receptor-positive and human epidermal growth factor receptor 2-negative …
with hormone receptor-positive and human epidermal growth factor receptor 2-negative …
Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China
Q Wei, YT Xu, W Liu, X Guan - Cost Effectiveness and Resource Allocation, 2023 - Springer
Objective The aim of this article is to evaluate the cost-effectiveness of abemaciclib plus
endocrine therapy (ABE+ ET) vs. ET as adjuvant treatment for high-risk hormone receptor …
endocrine therapy (ABE+ ET) vs. ET as adjuvant treatment for high-risk hormone receptor …
Cost-Effectiveness of three poliovirus immunization schedules in Shanghai, China
J Ren, H Maimaiti, X Sun, Z Huang, J Liu, J Yang, Z Li… - Vaccines, 2021 - mdpi.com
In Shanghai, China, a polio immunization schedule of four inactivated polio vaccines (IPV)
has been implemented since 2020, replacing the schedules of a combination of two IPVs …
has been implemented since 2020, replacing the schedules of a combination of two IPVs …
Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2-advanced or metastatic breast cancer? A US payer perspective …
BACKGROUND: Breast cancer is the most prevalent type of cancer in women in the United
States. Ribociclib plus fulvestrant combination therapy gained US Food and Drug …
States. Ribociclib plus fulvestrant combination therapy gained US Food and Drug …
Impact of CSR and Environmental Sustainability Orientation on Environmental Performance of South Asian SMEs: Mediating Effect of Green HRM
Purpose–There are plenty of studies investigating the impact of CSR and environmental
sustainability orientation (ESO) on environmental performance however there have been a …
sustainability orientation (ESO) on environmental performance however there have been a …
An Economic and Regulatory Analysis of Breast Cancer Drugs Approved by the US Food and Drug Administration
AJM Althomali - 2023 - search.proquest.com
Results As of December 31, 2022, the FDA approved 30 drugs including 23 new molecular
entities and 7 new biologics, with 60 indications for different stages of breast cancer and 71 …
entities and 7 new biologics, with 60 indications for different stages of breast cancer and 71 …